Abstract |
People with pre-hypertension ( high blood pressure but below the conventional threshold for intervention with antihypertensive drugs) undoubtedly have increased risk of cardiovascular and other complications. However, the vast majority has low absolute risk and whether treatment would be beneficial is uncertain. While pharmacotherapy has attractions from a public health perspective, clinicians and crucially those with pre-hypertension require robust evidence that drug treatment will lead to short term as well as long term gains. Any changes in recommendations should await adequately powered outcome studies which provide solid evidence of the magnitude of absolute risk reduction in treating pre-hypertension and assessment of the cost-effectiveness.
|
Authors | Gordon McInnes |
Journal | British journal of clinical pharmacology
(Br J Clin Pharmacol)
Vol. 73
Issue 2
Pg. 187-93
(Feb 2012)
ISSN: 1365-2125 [Electronic] England |
PMID | 21883385
(Publication Type: Journal Article, Review)
|
Copyright | © 2011 The Author. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society. |
Chemical References |
|
Topics |
- Antihypertensive Agents
(administration & dosage)
- Blood Pressure
(drug effects, physiology)
- Blood Pressure Determination
(standards)
- Humans
- Hypertension
(drug therapy)
- Meta-Analysis as Topic
- Prehypertension
(drug therapy)
- Randomized Controlled Trials as Topic
- Risk Factors
|